USE OF A COMPUTERIZED CLINICAL DECISION SUPPORT (CCDS) TOOL IN PRIMARY CARE INCREASES RATES OF CONFIRMATORY TESTING IN PATIENTS WITH METABOLIC ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AT RISK FOR ADVANCED LIVER FIBROSIS: A PILOT STUDY

被引：0
|
作者：
Miller, James [1 ]
Xiao, Ted [1 ]
Witek, Lauren [1 ]
Bundy, Richa [1 ]
Moses, Adam [1 ]
Obermiller, Corey [1 ]
Dharod, Ajay [1 ]
Russo, Mark [2 ]
Rudnick, Sean [3 ]
机构：
[1] Wake Forest Univ, Sch Med, Winston Salem, NC 27101 USA
[2] Carolinas Med Ctr, Charlotte, NC USA
[3] Atrium Hlth Wake Forest Baptist, Winston Salem, NC USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1185
引用
收藏
页码：S903 / S904
页数：2
相关论文
共 41 条
  • [1] Statin prescriptions and progression to a high-risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Schreiner, Andrew
    Zhang, Jingwen
    Gebregziabher, Mulugeta
    JOURNAL OF HEPATOLOGY, 2024, 80 : S614 - S614
  • [2] SUBOPTIMAL ASSESSMENT OF FIBROSIS IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PRIMARY CARE VERSUS LIVER CLINIC SETTINGS
    Nguyen, Brian T.
    Nguyen, Vy H.
    Park, Jung Eun
    Gudapati, Surya T.
    Maeda, Mayumi
    Kam, Leslie Y.
    Cheung, Ramsey
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2024, 166 (05) : S1651 - S1652
  • [3] Real world evaluation of a primary care pathway for the assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)
    Ahmad, Basil
    Mitchell, Oliver
    Pannifex, Sally
    Singanayagam, Arjuna
    Hughes, Sarah
    Clark, Sarah
    Yalcin, Metin
    Williams, Nicola
    Davie, Sarah
    Forton, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S523 - S523
  • [4] DIABETES RISK INDEX IN INDIVIDUALS WITH PCOS IS ASSOCIATED METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), CLINICALLY SIGNIFICANT FIBROSIS AND ADVANCED FIBROSIS
    Samala, Niharika
    Murthy, Sreemala
    Naidu, Suneetha
    Vilar-Gomez, Eduardo
    Chalasani, Naga
    HEPATOLOGY, 2024, 80 : S651 - S651
  • [5] Objective Measures of Cardiometabolic Risk and Advanced Fibrosis Risk Progression in Primary Care Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Schreiner, Andrew D.
    Zhang, Jingwen
    Moran, William P.
    Koch, David G.
    Marsden, Justin
    Bays, Chloe
    Mauldin, Patrick D.
    Gebregziabher, Mulugeta
    ENDOCRINE PRACTICE, 2024, 30 (11) : 1015 - 1022
  • [6] Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients
    Dabbah, Shoham
    Ben Yakov, Gil
    Kaufmann, Monika-Inda
    Cohen-Ezra, Oranit
    Likhter, Maria
    Davidov, Yana
    Ben Ari, Ziv
    MINERVA GASTROENTEROLOGY, 2024, 70 (03): : 322 - 331
  • [7] Improving the Screening and Management of Underserved Patients With Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Primary Care Setting
    Zhao, Danzhu
    Paladiya, Ruchir Damjibhai.
    Frondella, Amanda
    Bambara, Nicole
    Khoury, Neil
    Vergara, Cunegundo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1291 - S1291
  • [8] Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for use in reflex testing algorithms for metabolic dysfunction-associated steatotic liver disease (MASLD)
    van Son, Koen C.
    van Dijk, Anne-Marieke
    Driessen, Stan
    Mak, Anne Linde
    Witjes, Julia J.
    Houttu, Veera A. T.
    Zwirs, Diona
    Nieuwdorp, Max
    van den Born, Bert-Jan H.
    Fischer, Johan C.
    Tushuizen, Maarten E.
    Drenth, Joost P. H.
    Hamer, Henrike M.
    Beuers, Ulrich H. W.
    Verheij, Joanne
    Holleboom, Adriaan Georgius
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2024, 62 (11) : e236 - e239
  • [9] DEGREE OF METABOLIC DYSFUNCTION IS LINKED TO STEATOHEPATITIS (MASH), FIBROSIS, AND HIGHER CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Kim, David
    Abboud, Yazan
    Ismail, Mohamed
    Goyal, Ritik Mahaveer
    Pyrsopoulos, Nikolaos
    Kim, Hyunseok
    Hajifathalian, Kaveh
    Al-Khazraji, Ahmed
    HEPATOLOGY, 2024, 80 : S441 - S442
  • [10] Screening for Presence of High-Risk Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) In the US Primary Care Is Cost Effective
    Younossi, Zobair
    Paik, James M.
    Henry, Linda
    Stepanova, Maria
    Nader, Fatema
    DIABETES, 2024, 73
12345